In Vitro Comparison Of Generic And Branded Formulations Of Ceftazidime Using Standard Strain Of Pseudomonas.

ABSTRACT

Background& Objective: Use of generic medicines has been increasing in recent years as a cost saving measure in health care provision. But, there is an uncertainty about whether the quality of a generic medicine is equal to, greater than or less than its equivalent brand-name drug. Its quality must be evaluated in vitro and in vivo in order to confirm their suitability for therapeutic use. Here, we have done in vitro comparison of generic and brand formulation of ceftazidime against pseudomonas standard strain (ATCC 27853). Methodology: One generic and three brands of ceftazidime were selected for in vitro comparison. Microbiological assays were used to establish the Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) against pseudomonas standard strain (ATCC 27853) according CLSI (Clinical Laboratory Standard Institutes) guidelines. Results: The MIC values of the ceftazidime samples evaluated (Brand and generics) were the same for pseudomonas standard strain tested, indicating that all products behaved similarly. The MBC values were very similar for all samples. Overall, therefore, the results showed no significant differences among samples. Conclusion: Reference method MIC and MBC testing of ceftazidime against pseudomonas has demonstrated no significant difference in in vitro activity between generic and brand products.